Log InRegister
New Product Spotlight: NET Fragment Assay Kit (MPO-DNA)
Featured Article from 2026-07-23
Cayman’s new NET Fragment Assay Kit (MPO-DNA) allows for qualitative assessment of NETosis via the detection of MPO-DNA complexes (i.e., NET fragments) in human plasma and cell culture supernatants. This immunometric assay kit includes all necessary reagents and uses a straightforward protocol that provides rapid results in under four hours.
Off-Patent Drugs as Inspiration for New Therapies
Featured Article from 2025-10-24
Drug repurposing, also known as drug repositioning, is a strategy to discover novel indications for approved drugs. Repurposed drugs save 5-7 years in development time and cost $300 million on average compared with newly discovered drugs, which take 10-15 years to be developed and can cost $2-3 billion. Approximately one-third of new FDA approvals are for repurposed drugs, highlighting their significant contribution to modern medicine.
Cayman’s Off-Patent Drug Screening Library contains approximately 607 compounds to streamline drug repurposing studies.
Strategies to Ensure the Purity of PEGylated Lipids in Lipid Nanoparticles
Featured Article from 2025-05-13
The increasing variety and complexity of PEGylated lipids in lipid nanoparticles (LNPs) has led to issues that include lack of formalized nomenclature, confusion about what quality specifications are appropriate or necessary, and lack of standardized methods for appropriate characterization of identity and purity.
In this article, we shed light on these challenges and provide strategies for ensuring the quality and purity of PEGylated lipids in LNPs.
Five Ways Our Scientists Helped Make Research Possible
Five Ways Our Scientists Helped Make Research Possible
Article from 2024-07-26
Cayman is more than a supplier of products and services for life science research. We are scientists. We work collaboratively with fellow scientists in academia, biotechnology, and pharmaceutical industries, combining our expertise to solve complex problems and advancing our collective understanding in our shared field of study.
Discover the ways that Cayman scientists helped make research possible for these scientists in these papers published in 2024.
Discover LipidLaunch™: Lipid Nanoparticle Research Tools for RNA Therapies
Article from 2024-04-15
Cayman’s LipidLaunch™ research-ready LNPs and reagent kits support the entire LNP research and development process, offering tailored solutions from discovery to bioanalysis.
Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies
Press Release from 2024-02-22
Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits. The LipidLaunch™ product line is the latest addition to the company's portfolio of LNP research tools and reflects the company's legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.
LNPs Beyond mRNA Vaccines – Where Do We Go from Here?
LNPs Beyond mRNA Vaccines – Where Do We Go from Here?
Article from 2023-10-31
Lipid nanoparticles (LNPs) are primed to revolutionize modern medicine. This technology has immense possibilities to evolve beyond infectious disease to reach targets once considered undruggable and treat a near infinite number of conditions. But the field is still in its infancy, and there are a number of challenges yet to overcome to unlock the full potential of LNPs.
An Introduction to Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures
Article from 2022-02-23
Lipid nanoparticles (LNPs) have great potential to revolutionize the development of new therapeutics but preparing and using LNPs can seem difficult. This guide provides a comprehensive overview of LNP design, preparation, and use, and includes simple protocols and tips to follow for each step. Continue reading to start exploring LNPs in your research.
The Heads and Tails of Lipid-Based Drug Delivery
Article from 2022-01-25
Lipid-based drug delivery (LBDD) systems are customizable platforms for the targeted delivery of pharmaceuticals and other therapeutic agents to cells and tissues. By leveraging the biophysical properties of lipids, researchers can achieve an assortment of LBDD systems that encapsulate and deliver a wide variety of biomolecules.
Neutralizing Antibody Analysis Post COVID-19 Infection or Vaccination
Article from 2021-09-08
Cayman’s Bioanalysis & Assay Development Services partnered with GenScript to examine the onset and durability of the COVID-19 vaccine-induced neutralizing antibody response.
Vitamin D Supplementation for COVID-19: Can It Really Help?
Article from 2021-08-19
Vitamin D offers a few compelling reasons to be helpful in the context of COVID-19 by increasing antimicrobial peptide expression and anti-inflammatory effects that support immune defense and acting directly on ACE2, the receptor for SARS-CoV-2.
Rare Diseases Research Funded by $345,757 in Grants from CABRI
Rare Diseases Research Funded by $345,757 in Grants from CABRI
Press Release from 2021-08-03
In its ongoing commitment to funding research for new treatments for rare diseases, Cayman Biomedical Research Institute (CABRI) has announced its principal investigator grant recipients for the 2021 academic year.
Promising Natural Products for Treating SARS-CoV-2 Infection
Article from 2021-07-27
Natural products have attracted considerable attention as potential agents to combat SARS-CoV-2. Molecular docking analysis of various natural products in complex with the viral main protease, RNA-dependent RNA polymerase, and spike protein along with the host ACE2 receptor has revealed multiple promising candidates with excellent binding affinity.
In It for the Long Haul: Research Tools for Long COVID Syndrome
Article from 2021-07-20
Cayman is poised to supply research tools to support scientists addressing the symptoms and examining the causes of Long COVID. A road map for treatment options is being drawn from other conditions with overlapping symptoms that can arise suddenly post viral infection.
Lipid-Based Nano Drug Delivery
Article from 2021-05-20
Drug delivery systems using lipid-based nanoparticles offer significant advantages in drug development, boosting bioavailability, reducing toxicity, and enabling the administration of therapeutics that are prone to instability like mRNA. Cayman offers tools for the research and development of lipid nanoparticles.
The Precellys® Emulsion Kit Produces Injectable Emulsions for Immunology Research
Article from 2021-03-08
Injectable emulsions are commonly used in a variety of immunological studies, including the generation of animal models of autoimmune diseases and preparation of adjuvants for vaccine and immunotherapy development. The Precellys® Minilys Personal Tissue Homogenizer can be used to prepare high-quality injectable emulsions with the Precellys® Emulsion Kit.
Unraveling Immune Dysregulation and Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Article from 2021-02-18
Cayman's Cellular Metabolism expert in collaboration with University of Michigan researchers offers an insightful review of the cellular and mitochondrial implications of this debilitating disease and the identification of multiple targets for potential pharmacological intervention.
Detecting Neutralizing Antibody Responses to COVID-19
Article from 2021-02-09
Cayman’s Bioanalysis & Assay Development Services help validate an assay that allows direct assessment of the capacity of inhibitory immunoglobins or synthetic compounds to block the binding of spike protein to ACE2.
Developing Biomarkers to Predict COVID-19 Disease Severity
Article from 2021-02-03
Cayman’s Lipidomics Services team use their targeted eicosanoid and oxylipin panels to help researchers at the University of Rochester detect biomarkers of inflammation in COVID-19.
Concerning Variants of SARS-CoV-2
Article from 2021-01-25
The simultaneous emergence of different SARS-CoV-2 lineages from different countries around the world each carrying mutations in the spike protein receptor binding site reveal convergent selective pressure on SARS-CoV-2 to create an advantage towards its transmissibility and reinfection of individuals.
PANoptosis: An Inflammatory Programmed Cell Death Pathway
Article from 2021-01-22
PANoptosis, which involves the collective activation of pyroptosis, apoptosis, and necroptosis, is a newly described inflammatory programmed cell death pathway induced by bacterial and viral pathogens. Learn about its mechanism and regulation, as well as recent research suggesting a role for PANoptosis in COVID-19-associated inflammation.
Remdesivir: The First FDA-Approved Treatment for COVID-19
Article from 2020-12-04
In an encouraging step in the fight against COVID-19, the antiviral remdesivir is the first drug approved by the FDA for the treatment of this disease. Here we discuss the metabolism of remdesivir to a nucleoside triphosphate that can be mistakenly incorporated into the genome of RNA-based viruses by the viral replication machinery, confounding the viral replication process.
Cayman Breaks Ground on State-of-the-Art Facility Projecting Future Growth in R&D
Press Release from 2020-11-05
Cayman held a groundbreaking ceremony to start the buildout of a $20 million research and development facility at its headquarters in Ann Arbor, MI.
Rapid Seropositivity Test Monitors Immune Response to SARS-CoV-2
Rapid Seropositivity Test Monitors Immune Response to SARS-CoV-2
Press Release from 2020-08-06
Cayman scientists have developed a SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit to enable semi-quantitative identification of neutralizing antibodies in human plasma or serum to the novel coronavirus that causes COVID-19.
Cayman’s 2020 Women in Research Grant Recipients
Cayman’s 2020 Women in Research Grant Recipients
Article from 2020-07-22
To commemorate Women’s History Month and further our mission of helping make research possible, Cayman awarded forty $1,000 research grants. Here are the researchers Cayman is proud to be supporting.
Contact Info
Cayman Chemical1180 East Ellsworth RoadAnn Arbor, Michigan 48108 USAToll Free: (800) 364-9897(USA and Canada only)Fax: (734) 971-3640
